GLP-1 medications have become a major part of the national conversation about obesity, diabetes and prescription drug costs as more Americans use treatments such as Ozempic, Wegovy and Zepbound. That debate has sharpened around President Donald Trump’s repeated references to the medicines as “the fat drug” or “fat pill,” language he used in public remarks in 2025 and again in 2026 while discussing prices and access. Doctors and obesity specialists say the wording matters because it can frame treatment around ridicule instead of chronic disease care.
Trump’s comments put GLP-1 language under scrutiny
Trump publicly used the nickname in official remarks on September 22, 2025, according to a Factbase transcript published by Roll Call, when he referred to Ozempic pricing and said he called it “the fat pill or the fat drug.” Federal records compiled by the Government Publishing Office also show Trump using similar language in 2025, including references to a “fat drug” and “fat killer” while discussing GLP-1 price cuts and access. Those remarks tied the medications to a White House message about lowering consumer costs rather than to a new medical policy on obesity terminology.
The scale of the issue is significant because GLP-1 use has expanded well beyond a niche treatment market. KFF reported in a November 2025 poll that 12% of U.S. adults, or about one in eight, said they were currently taking a GLP-1 drug for weight loss, diabetes or another condition. Reuters also reported in February 2026 that the TrumpRx launch focused heavily on negotiated discounts for popular GLP-1 weight-loss drugs.
Physicians and advocacy groups have pushed back on the label. The Obesity Action Coalition states that weight bias is dehumanizing and damaging, while NIH guidance recommends neutral, person-first terms when writing outside a scientific or clinical study context. A 2021 systematic review indexed by PubMed found that health care professionals themselves can hold both implicit and explicit weight bias, which specialists say is one reason public language from elected officials can carry added weight.
Because Trump’s remarks were delivered at national events and in White House settings, the impact is not limited to one state or city. Patients in the United States are already encountering GLP-1 treatment through primary care offices, endocrinology clinics, telehealth platforms and direct-to-consumer programs, and doctors say public shorthand can shape how those conversations begin. The federal government has not released any state-by-state accounting showing where Trump’s rhetoric has had measurable effects on prescribing, complaints or patient outcomes.
What is confirmed is that weight stigma is already a documented issue inside the health system. An American Family Physician editorial citing obesity-care research said about half of higher-weight patients experience weight bias in health care settings. StatPearls, a clinical reference indexed by NCBI Bookshelf, also states that weight bias and stigma in medical settings are prevalent and can undermine treatment adherence and outcomes.
Doctors who object to terms like “fat drug” argue that the concern is not political branding alone but how patients hear it. GLP-1 drugs are prescribed for diabetes, obesity and other related conditions, and many physicians say reducing them to a joke or insult can discourage patients from seeking care. No federal agency has issued a sanction or formal warning over Trump’s phrasing, and the White House has continued to frame its GLP-1 messaging around affordability.
The broader context is that obesity medicine has spent years trying to move toward person-first, less stigmatizing language. A joint clinical perspective published in 2024 and archived in PMC noted that the American Medical Association has encouraged person-first language and discouraged stigmatizing terms including “fat” when referring to patients affected by obesity. NIH’s style guidance similarly advises neutral descriptions such as “person with higher weight” outside narrow clinical contexts.
That shift reflects evidence that stigma can affect care, not just tone. A review article in PMC on weight bias and stigma reported that patients with obesity frequently identify physicians as a common source of bias, and that some women with obesity report avoiding health care altogether. The Obesity Society said in a 2025 statement supporting new standards of care that reducing bias is part of improving access to treatment and outcomes for people living with obesity.
For patients and families, the practical takeaway is that GLP-1 medications remain prescription drugs used for specific medical indications, regardless of political nicknames. Coverage, eligibility and out-of-pocket costs still depend on insurers, employers, federal programs and manufacturer discount arrangements, and Reuters reported some employers were already considering scaling back coverage because of sustained costs. The public debate over Trump’s language is likely to continue alongside a larger policy fight over how obesity is discussed, treated and paid for in the U.S. healthcare system.